T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
Clinical benefit scores of many anticancer medications approved during the study period seemed to improve at data follow-up.
Nearly half of the patients with advanced HER2-positive breast cancer enrolled in the randomized, phase II HER2CLIMB trial had disease that had metastasized to the brain.
The VA NPOP is a program established to provide access to next-generation sequencing for veterans with advanced solid tumors.
An analysis utilized the baseline characteristics of patients with pretreated ovarian cancer enrolled in a phase 3 trial to evaluate lifestyle interventions.
Updated results confirmed benefit seen in primary analysis.
Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.
Trememlimumab thought to induce immune response.
Updated findings from KEYNOTE-426 showed that frontline pembrolizumab-axitinib continued to be associated with improved PFS and OS compared with sunitinib in advanced RCC.
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
The Alexander study was designed to test if dual-targeting of CD19 and CD22 would reduce the likelihood of antigen escape.
PI3KCA is mutated in approximately 40% of patients with HR-positive, HER2-negative advanced breast cancer, and is associated with treatment resistance and poor outcomes.
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.